Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis

The following video is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 .

CHICAGO – Christopher T. Ritchlin, MD, MPH, University of Rochester Medical Center, discusses updated bimekizumab data from the BE-ACTIVE trial presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, in Chicago, Illinois.

BE ACTIVE is a randomized, double‑blind, placebo-controlled trial assessing the dose response, long-term efficacy, and safety of bimekizumab in adults with psoriatic arthritis.

Follow @DermAdvisor

Disclosures: Dr Ritchlin has received research grants from UCB, Amgen, Abbvie, and consulting fees from UCB, Amgen, AbbVie, Pfizer, Novartis, Lilly.

This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.

This article originally appeared on Rheumatology Advisor